---

25 High-Yield Conceptual MCQs: Calcium Channel Blockers

---

MCQ 1

Verapamil (phenylalkylamine) scores highest (5/5) for both cardiac contractility depression and SA/AV nodal effects. Dihydropyridines score 0-1 for conduction. - G&G, Table 31-2

---

MCQ 2

Ca2+ channel blockers produce their effects by binding to the α subunit of the L-type voltage-gated Ca2+ channels and reducing Ca2+ flux through the channel. - G&G, Mechanisms of Action

---

MCQ 3

"Verapamil was the first clinically available Ca2+ channel blocker; it is a congener of papaverine." - G&G, Historical Perspective

---

MCQ 4

"Ca2+ channel blockers, but not nitrates, have been shown to influence mortality and the incidence of MI favorably in variant angina; they should generally be included in therapy." - G&G, Variant Angina

---

MCQ 5

"Amlodipine and the other dihydropyridine agents are more selective as vasodilators and have less cardiac depressant effect than verapamil and diltiazem. Reflex sympathetic activation with slight tachycardia maintains or increases cardiac output in most patients given dihydropyridines." - Katzung, Chapter 11

---

MCQ 6

"Clevidipine is a newer member of this group that is formulated for intravenous use only. It has a rapid onset of action and has been used in acute hypertension occurring during surgery." Infused starting at 1-2 mg/h. - Katzung

---

MCQ 7

Verapamil = phenylalkylamine; diltiazem = benzothiazepine; nifedipine (and amlodipine, nicardipine, etc.) = dihydropyridines. - G&G, Chemistry

---

MCQ 8

"Some epidemiologic studies reported an increased risk of myocardial infarction or mortality in patients receiving short-acting nifedipine for hypertension. It is therefore recommended that short-acting oral dihydropyridines not be used for hypertension." - Katzung

---

MCQ 9

"In cardiac myocytes, the entry of extracellular Ca2+ causes a larger Ca2+ release from intracellular stores (Ca2+-induced Ca2+ release) and thereby initiates the contraction twitch." - G&G, Mechanisms of Action

---

MCQ 10

Nimodipine is listed among CCBs and is noted for its cerebral vascular selectivity, used for subarachnoid hemorrhage-associated vasospasm. It is also mentioned as "not available in the USA" for hypertension (nitrendipine), while nimodipine has a distinct CNS indication. - G&G, Chemistry; Katzung

---

MCQ 11

"Reflex sympathetic activation with slight tachycardia maintains or increases cardiac output in most patients given dihydropyridines." The peripheral vasodilation triggers a baroreceptor-mediated reflex. - Katzung

---

MCQ 12

"Diltiazem has intermediate actions." It scores 3/5 for vasodilation (vs 5/5 for amlodipine), 2/5 for contractility depression (vs 4/5 for verapamil), and 4/5 for AV conduction slowing. - G&G, Table 31-2; Katzung

---

MCQ 13

"Voltage-gated channels contain domains of homologous sequence that are arranged in tandem within a single large subunit." The α1 subunit has four homologous domains. - G&G, Mechanisms of Action

---

MCQ 14

"Intravenous nicardipine and clevidipine are available for the treatment of hypertension when oral therapy is not feasible. Nicardipine is typically infused at rates of 2-15 mg/h." - Katzung

---

MCQ 15

"In addition to the major channel-forming subunit (termed α), Ca2+ channels contain several other associated subunits (termed α2, β, γ, and δ)." - G&G

---

MCQ 16

"Verapamil has the greatest depressant effect on the heart and may decrease heart rate and cardiac output." This explains its contraindication with beta-blockers and in systolic heart failure. - Katzung

---

MCQ 17

"The work in the 1960s of Fleckenstein and colleagues led to the concept that drugs can alter cardiac and smooth muscle contraction by blocking the entry of Ca2+ into myocytes." - G&G, Historical Perspective

---

MCQ 18

"Increases in external concentrations of K+ and depolarizing electrical stimuli increase Ca2+ influx through voltage-gated, or 'potential operated,' channels." These are the targets of CCBs. - G&G

---

MCQ 19

CCBs reduce afterload (decreasing O2 demand) and dilate coronary arteries (increasing supply). In variant angina specifically, they reverse coronary vasospasm. Both supply and demand mechanisms are involved. - G&G

---

MCQ 20

"Sustained-release calcium blockers or calcium blockers with long half-lives provide smoother blood pressure control and are more appropriate for treatment of chronic hypertension." Short-acting dihydropyridines cause surge-and-crash BP patterns. - Katzung

---

MCQ 21

"Some calcium channel blockers, such as nifedipine and diltiazem, are used as tocolytic agents." - Katzung (referencing Rosen's Emergency Medicine context)

---

MCQ 22

"IV verapamil is useful to terminate fetal tachycardia." - Katzung

---

MCQ 23

Amlodipine (dihydropyridine) scores only 1/5 for cardiac contractility depression vs verapamil's 4/5. Verapamil's strong negative inotropy makes it dangerous in systolic dysfunction. - G&G, Table 31-2

---

MCQ 24

"Verapamil, diltiazem, and the dihydropyridine family (amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, nimodipine, and nitrendipine [the latter two not available in the USA])" - Katzung (Note: nimodipine IS available in USA for subarachnoid hemorrhage; nitrendipine is not.)

---

MCQ 25

"Many hormones and autocoids increase Ca2+ influx through so-called receptor-operated channels, whereas increases in external concentrations of K+ and depolarizing electrical stimuli increase Ca2+ influx through voltage-gated channels." - G&G, Mechanisms of Action

---

Summary Table

---

CALCIUM CHANNEL BLOCKERS (CCBs)

Complete Notes for University / NEET-PG / INICET Exams

---

1. HISTORICAL BACKGROUND

• Verapamil was the first clinically available CCB - a congener of papaverine (vasodilator alkaloid from opium poppy)
• Concept of Ca2+ entry blockade established by Fleckenstein et al., 1960s
• Hass & Hartfelder (1962) first reported that verapamil had negative inotropic and chronotropic effects distinct from other vasodilators
• Fleckenstein (1967): proposed the mechanism was inhibition of excitation-contraction coupling via reduced Ca2+ entry

---

2. CLASSIFICATION (Chemical)

NEET Mnemonic for DHPs: "No Fear Among Nice Clean Indian Ladies" = Nifedipine, Felodipine, Amlodipine, Nicardipine, Clevidipine, Isradipine, Lercanidipine

---

3. CALCIUM CHANNEL TYPES (Katzung Table 12-4) - HIGH YIELD

Key fact: All clinically used cardiovascular CCBs are exclusively L-type blockers. T-type blockers are used in some antiseizure drugs (e.g., ethosuximide mechanism).

---

4. MECHANISM OF ACTION

Target: α1 subunit of L-type voltage-gated Ca2+ channel

• Channels contain 4 homologous domains arranged in tandem within a single large α1 subunit
• Associated subunits: α2, β, γ, δ
• CCBs bind the α1 subunit → reduce Ca2+ flux through the channel

In Vascular Smooth Muscle

• Depolarization → voltage-gated (L-type) channels open → Ca2+ influx
• Ca2+ + calmodulin → activates myosin light-chain kinase (MLCK) → phosphorylates myosin light chain → actin-myosin interaction → tonic contraction
• CCBs block this → vasodilation (especially arterial)
• Important: CCBs do NOT significantly affect venous capacitance vessels at therapeutic doses → no significant preload reduction (unlike nitrates)

In Cardiac Myocytes (Working Myocardium)

• Na+ influx causes depolarization → L-type Ca2+ channels open → Ca2+ entry
• Ca2+ binds troponin C → relieves inhibition → actin-myosin interaction → contraction
• Ca2+ also triggers Ca2+-induced Ca2+ release (CICR) from SR
• CCBs reduce peak systolic Ca2+ transient → negative inotropy
• DHPs: peripheral vasodilation causes baroreceptor reflex → sympathetic activation → overcomes negative inotropy

In SA and AV Nodes (Pacemaker Tissue)

• SA/AV nodes depend on slow Ca2+ channels (not fast Na+ channels) for depolarization
• Verapamil: blocks activated AND inactivated L-type channels; slows recovery of the channel → greater effect on frequently firing tissues (use-dependent block) → slows SA rate, prolongs AV conduction and ERP
• Nifedipine (DHP): reduces slow inward current BUT does NOT affect rate of recovery of slow Ca2+ channel → at clinical doses, no direct effect on SA/AV node; instead, causes reflex tachycardia via sympathetic activation

---

5. COMPARATIVE PHARMACODYNAMIC EFFECTS (G&G Table 31-2)

High-yield summary:

• Most vasodilation: DHPs (amlodipine)
• Most cardiac depression (inotropy + chronotropy + dromotropy): Verapamil
• Intermediate effects: Diltiazem
• DHPs do NOT affect AV conduction (score 0) - safe in AV nodal disease

---

6. PHARMACOKINETICS (Katzung Table 12-5)

Key PK fact: Verapamil bioavailability only 20% due to extensive hepatic first-pass; oral doses much higher than IV (120-640 mg/day oral vs 5-10 mg IV bolus)

---

7. DRUG INTERACTIONS (HIGH YIELD)

---

8. THERAPEUTIC USES

A. Angina Pectoris

• First-line treatment - CCBs effective in ~90% of patients
• Mechanism: reverse coronary vasospasm
• CCBs but NOT nitrates reduce mortality and MI in variant angina
• May combine with nitrovasodilators
• Exclude drug-induced causes: cocaine, amphetamines, sumatriptan

• CCBs reduce "double product" (HR × systolic BP) = reduces O2 demand
• Second-line after β-blockers (β-blockers have better mortality evidence in stable angina)
• Combination DHP + β-blocker is better than either alone (β-blocker suppresses DHP-induced reflex tachycardia)
• DHP preferred in combination (no additive AV block risk)

• Short-acting nifedipine is CONTRAINDICATED (can worsen ischemia, increase adverse events)
• Diltiazem can be used in non-Q-wave MI to reduce post-infarction angina

B. Hypertension

• All CCBs (verapamil, diltiazem, all DHPs) are equally effective
• Short-acting oral nifedipine AVOIDED - associated with increased MI/mortality risk
• Preferred: long-acting (sustained-release) formulations
• IV forms for acute/perioperative hypertension:
  • Nicardipine: 2-15 mg/h
  • Clevidipine: start 1-2 mg/h → 4-6 mg/h (rapid onset, used in surgical setting)
  • Verapamil IV, Diltiazem IV also available

C. Supraventricular Tachyarrhythmias (CLASS IV Antiarrhythmics)

• Verapamil and Diltiazem only (NOT DHPs - dihydropyridines may precipitate arrhythmias)
• Uses:
  • PSVT (SVT): Adenosine is first choice; verapamil/diltiazem are alternatives
  • Rate control in AF/AFL
  • AVNRT, AVRT (re-entry through AV node)
• Verapamil IV: 5 mg bolus over 2-5 min → second 5 mg if needed
• Verapamil suppresses early and delayed afterdepolarizations - useful in triggered arrhythmias

CRITICAL WARNING: Never give IV verapamil to wide-complex tachycardia assumed to be SVT - if it is actually VT → hypotension + ventricular fibrillation

D. Other Uses

---

9. ADVERSE EFFECTS

Dihydropyridines (Nifedipine-like)

Lercanidipine causes less peripheral edema than other DHPs

Verapamil-specific

All CCBs

• Can aggravate gastroesophageal reflux
• Negative inotropy - all CCBs can worsen heart failure (exception: amlodipine does not increase mortality in non-ischemic HFrEF)

---

10. CONTRAINDICATIONS

---

11. SPECIAL SITUATIONS (EXAM TARGETS)

---

12. QUICK-REVISION HIGH-YIELD FACTS

1. First CCB introduced: Verapamil (1962, Hass & Hartfelder)
2. Verapamil derived from: Papaverine
3. CCBs block: L-type (Cav1) voltage-gated Ca2+ channels - α1 subunit
4. Only IV-available CCB: Clevidipine (also nicardipine and verapamil IV, diltiazem IV)
5. Longest half-life: Amlodipine (30-50 hours) → once daily dosing
6. Peripheral edema mechanism: Precapillary dilation, NOT fluid retention
7. Constipation: Verapamil (most common side effect)
8. Best bioavailability: Amlodipine (65-90%)
9. Worst bioavailability: Verapamil (20%), Nisoldipine (<10%)
10. AV nodal drug: Verapamil > Diltiazem >> Nifedipine (0 effect)
11. Use-dependent block: Verapamil (blocks activated AND inactivated channels)
12. DHPs + β-blocker combo: Ideal (β-blocker prevents DHP reflex tachycardia)
13. Verapamil + β-blocker combo: CONTRAINDICATED (excessive cardiac depression)
14. Verapamil + Digoxin: ↑ digoxin levels (inhibits P-gp + pharmacodynamic synergy)
15. Variant angina drug of choice: CCBs (reduce MI + mortality; nitrates don't)
16. SVT drug: Adenosine (first) → Verapamil/Diltiazem (second)
17. Wide complex tachycardia: NEVER give verapamil (may be VT → VF)
18. Nimodipine: Subarachnoid hemorrhage (cerebrovascular specificity)
19. Amlodipine in HF: Safe (does not increase mortality in non-ischemic HFrEF)
20. Gingival hyperplasia: Nifedipine (classic side effect)

---

13. COMPARISON WITH β-BLOCKERS IN ANGINA

---

1. Historical background - Fleckenstein, verapamil from papaverine
2. Classification - PAA / BTZ / DHP with all members + mnemonic
3. Calcium channel types table - L, T, N, P/Q, R (very high yield for NEET-PG)
4. Mechanism of action - vascular, cardiac, nodal tissue separately explained
5. Comparative pharmacodynamics table - vasodilation vs inotropy vs chronotropy (scores)
6. Pharmacokinetics table - bioavailability, half-life, dosing for each drug
7. Drug interactions - verapamil + digoxin, verapamil + β-blockers, CYP3A4 interactions
8. Therapeutic uses - angina (variant/stable/unstable), HTN, arrhythmias, and 8+ other uses
9. Adverse effects - DHP vs verapamil-specific + mechanism of peripheral edema
10. Contraindications - WPW + AF being a classic exam trap
11. Special situations table - which CCB to choose in which clinical scenario
12. 20 quick-revision facts - ideal for last-minute revision
13. CCBs vs β-blockers comparison - frequently tested